Memphasys has inked its first exclusive commercialization agreement in South-East Asia with TMSC Vietnam, targeting the fast-growing Vietnamese IVF sector with its Felix™ sperm separation system. The two-year contract, valued at A$530,000, hinges on regulatory approval expected by August 2026.
- Exclusive two-year Felix™ distribution deal in Vietnam
- Contract valued at A$530,000 with volume growth over term
- Vietnam IVF market forecast to exceed US$200 million by 2029
- Regulatory approval expected August 2026 before sales start
- Commercial model mirrors proven direct sales partnerships
Strategic Expansion into Vietnam’s Fertility Market
Memphasys Limited (ASX:MEM) has taken a significant step beyond its established European, MENA, Japan, and Indian markets by securing an exclusive two-year commercialisation agreement with TMSC Viet Nam Medical Technology Company Limited. This deal marks Memphasys’ first foothold in South-East Asia, specifically targeting Vietnam’s rapidly expanding assisted reproductive technology (ART) sector.
Vietnam’s IVF market, valued at approximately US$141 million in 2023 and projected to surpass US$200 million by 2029, offers fertile ground for Memphasys’ Felix™ System. The country’s IVF clinics, particularly in Hanoi and Ho Chi Minh City, have gained a reputation for success rates comparable to leading Western centres, underpinned by skilled clinicians and expanding infrastructure. Demand for advanced sperm selection technologies like Felix™ is expected to rise as clinics seek to enhance IVF outcomes and laboratory efficiency.
Deal Structure and Regulatory Pathway
The agreement, valued at A$530,000 over two years, anticipates a volume-driven increase from A$205,000 in the first year to A$325,000 in the second, reflecting growing clinical adoption. Sales will commence following regulatory approval from Vietnamese health authorities, with Felix™ classified as a Class B medical device. Registration is expected to be completed by August 2026, enabling a swift commercial launch.
Ahead of full market entry, TMSC Vietnam has ordered an initial batch of 100 Felix™ cartridges and three consoles to facilitate in-market testing and clinical preparation. Subsequent orders will be delivered quarterly throughout the contract term, aligning with the company’s growth expectations.
Leveraging Local Expertise Through TMSC Vietnam
TMSC Vietnam brings a strong local presence and expertise in reproductive health technology, with a portfolio that includes diagnostics, digital health tools, and male fertility products. Their existing partnerships with global medical technology firms and experience in male reproductive health position them well to introduce Felix™ to Vietnam’s fertility clinics.
Memphasys will adopt its proven direct engagement commercial model, working closely with TMSC Vietnam to drive product education, clinical positioning, and market development. This approach has underpinned success in other regions, including the MENA market, where Memphasys has secured substantial orders and expanded its footprint.
Outlook and Next Steps
Key upcoming milestones include the completion of the Vietnamese regulatory submission process by August 2026 and the commencement of in-market testing with the initial order. The first commercial order, expected in the September quarter of 2026, is projected at approximately A$50,000. Memphasys also plans to continue developing its broader South-East Asian distribution strategy, signalling ambitions for further regional expansion.
Chair of Memphasys’ Commercialisation Committee, Marjan Mikel, emphasised the strategic fit of Vietnam’s sophisticated IVF market for Felix™, highlighting the scalability of Memphasys’ commercial model. Meanwhile, TMSC Vietnam’s director, Truong Cam Van, expressed confidence that Felix™ meets a genuine clinical need and is poised to become a standard in Vietnamese fertility clinics.
Bottom Line?
Memphasys’ entry into Vietnam’s IVF market via a $530,000 contract underscores its strategic push into high-growth fertility sectors, with regulatory approval and initial sales in 2026 key to validating this expansion.
Questions in the middle?
- Will regulatory approval in Vietnam proceed on schedule to enable the planned commercial launch?
- How quickly will Vietnamese IVF clinics adopt Felix™, and what impact will this have on Memphasys’ revenue trajectory?
- Could the Vietnam deal serve as a springboard for broader South-East Asian market penetration?